Presented below is Management's Discussion and Analysis of Financial Condition
and Results of Operations (or "MD&A") for IMAX Corporation and its consolidated
subsidiaries ("IMAX" or the "Company") for the three and six months ended
June 30, 2020 and 2019. MD&A should be read in conjunction with Note
14, "Segment Reporting" in the accompanying Condensed Consolidated Financial
Statements in Item 1.

The Company indirectly owns approximately 69.81% of IMAX China Holding, Inc.
("IMAX China"), whose shares trade on the Hong Kong Stock Exchange. IMAX China
is a consolidated subsidiary of the Company.

SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION



Certain statements included in this quarterly report may constitute
"forward-looking statements" within the meaning of the United States Private
Securities Litigation Reform Act of 1995. These forward-looking statements
include, but are not limited to, references to business and technology
strategies and measures to implement strategies, competitive strengths, goals,
expansion and growth of business, operations and technology, future capital
expenditures (including the amount and nature thereof), plans and references to
the future success of the Company and expectations regarding its future
operating, financial and technological results. These forward-looking statements
are based on certain assumptions and analyses made by the Company in light of
its experience and its perception of historical trends, current conditions and
expected future developments, as well as other factors it believes are
appropriate in the circumstances. However, whether actual results and
developments will conform with the expectations and predictions of the Company
is subject to a number of risks and uncertainties, including, but not limited
to, risks associated with investments and operations in foreign jurisdictions
and any future international expansion, including those related to economic,
political and regulatory policies of local governments and laws and policies of
the United States and Canada; risks related to the Company's growth and
operations in China; the performance of IMAX DMR® films; the signing of IMAX
Theater System agreements; conditions, changes and developments in the
commercial exhibition industry; risks related to currency fluctuations; the
potential impact of increased competition in the markets within which the
Company operates; competitive actions by other companies; the failure to respond
to change and advancements in digital technology; risks relating to recent
consolidation among commercial exhibitors and movie studios; risks related to
new business initiatives; conditions in the in-home and out-of-home
entertainment industries; the opportunities (or lack thereof) that may be
presented to and pursued by the Company; risks related to cyber-security and
data privacy; risks related to the Company's inability to protect its
intellectual property; general economic, market or business conditions; the
failure to convert IMAX Theater System backlog into revenue; changes in laws or
regulations; the failure to fully realize the projected cost savings and
benefits from any of the Company's restructuring initiatives; the impact of
COVID-19 on our business, financial condition, and results of operations and on
the businesses of our customers and exhibitor partners; and other factors, many
of which are beyond the control of the Company. Consequently, all of the
forward-looking statements made in this quarterly report are qualified by these
cautionary statements, and actual results or anticipated developments by the
Company may not be realized, and even if substantially realized, may not have
the expected consequences to, or effects on, the Company. The Company undertakes
no obligation to update publicly or otherwise revise any forward-looking
information, whether as a result of new information, future events or otherwise.

The Company makes available, free of charge, its Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and any
amendments to such reports, as soon as reasonably practicable after such filings
have been made with the United States Securities and Exchange Commission (the
"SEC"). Reports may be obtained free of charge through the SEC's website at
www.sec.gov and through the Company's website at www.imax.com or by calling the
Company's Investor Relations Department at 212-821-0100. No information included
on the Company's website shall be deemed included or otherwise incorporated into
this filing, except where expressly indicated.

The information posted on the Company's corporate and Investor Relations websites may be deemed material to investors. Accordingly, investors, media and others interested in the Company should monitor the Company's websites in addition to the Company's press releases, SEC filings and public conference calls and webcasts.





IMAX®, IMAX® Dome, IMAX® 3D, IMAX® 3D Dome, Experience It In IMAX®, The IMAX
Experience®, An IMAX Experience®, An IMAX 3D Experience®, IMAX DMR®, DMR®, IMAX
nXos® and Films to the Fullest®, are trademarks and trade names of the Company
or its subsidiaries that are registered or otherwise protected under laws of
various jurisdictions.


                                       44

--------------------------------------------------------------------------------

OVERVIEW



IMAX is one of the world's leading entertainment technology companies,
specializing in technological innovations powering the presentation of some of
today's most immersive entertainment experiences. Through its proprietary
software, theater architecture, patented intellectual property and specialized
equipment, IMAX offers a unique end-to-end cinematic solution to create the
highest-quality, most immersive motion picture and other entertainment event
experiences for which the IMAX® brand has become known globally. Top filmmakers
and movie studios utilize the cutting-edge visual and sound technology of IMAX
to connect with audiences in innovative ways, and, as a result, IMAX's network
is among the most important and successful distribution platforms for major
films and other events around the world.

The Company leverages its innovative technology and engineering in all aspects
of its business, which principally consists of the digital remastering of films
and other presentations into the IMAX format ("IMAX DMR") and the sale or lease
of premium IMAX theater systems ("IMAX Theater Systems").

IMAX Theater Systems are based on proprietary and patented image, audio and
other technology developed over the course of the Company's 52-year history. The
customers who purchase or lease IMAX Theater Systems are theater exhibitors that
operate commercial theaters (particularly multiplexes), museums, science
centers, or destination entertainment sites. The Company generally does not own
the theaters in the IMAX network, but licenses the use of its trademarks along
with the sale or lease of the IMAX Theater System.

As at June 30, 2020, there were 1,615 IMAX Theater Systems operating in 81
countries and territories, including 1,527 commercial multiplexes, 13 commercial
destinations and 75 institutional locations. This compares to 1,541 IMAX Theater
Systems operating in 81 countries and territories as of June 30, 2019 including
1,445 commercial multiplexes, 15 commercial destinations and 81 institutional
locations. (See the table below under "IMAX Network and Backlog" for additional
information on the composition of the IMAX network.)

The IMAX Theater System provides the Company's exhibitor customers with a combination of the following benefits:

• the ability to exhibit content that has undergone the IMAX DMR® conversion

process, which results in higher image and sound fidelity than conventional

cinema experiences;

• advanced, high-resolution projectors with specialized equipment and automated


     theater control systems, which generate significantly more contrast and
     brightness than conventional theater systems;


  •  large screens and proprietary theater geometry, which result in a

substantially larger field of view so that the screen extends to the edge of

a viewer's peripheral vision and creates more realistic images;

• advanced sound system components, which deliver more expansive sound imagery

and pinpointed origination of sound to any specific spot in an IMAX theater;

• specialized theater acoustics, which result in a four-fold reduction in


     background noise; and


  • a license to the globally recognized IMAX brand.


In addition, certain movies shown in IMAX theaters are filmed using proprietary
IMAX film and IMAX certified digital cameras, which offer filmmakers customized
guidance and workflow process to provide further enhanced and differentiated
image quality and a film aspect ratio that delivers up to 26% more image onto a
movie screen.

Together these components cause audiences in IMAX theaters to feel as if they are a part of the on-screen action, creating a more intense, immersive and exciting experience than a traditional theater.



As a result of the engineering and scientific achievements that are a hallmark
of The IMAX Experience®, the Company's exhibitor customers typically charge a
premium for IMAX DMR films over films exhibited in their other auditoriums. The
premium pricing, combined with the higher attendance levels associated with IMAX
DMR films, generates incremental box office for the Company's exhibitor
customers and for the movie studios releasing their films to the IMAX
network. The incremental box office generated by IMAX DMR films has helped
establish IMAX as a key premium distribution and marketing platform for
Hollywood blockbuster films.

                                       45

--------------------------------------------------------------------------------


As one of the world's leaders in entertainment technology, the Company strives
to remain at the forefront of advancements in cinema technology. In 2018, the
Company introduced IMAX with Laser, a laser projection system designed for IMAX
theaters in commercial multiplexes, which represents a further evolution of
IMAX's proprietary technology. The Company believes that IMAX with Laser
delivers increased resolution, sharper and brighter images, deeper contrast as
well as the widest range of colors available to filmmakers today. The Company
further believes that IMAX with Laser is helping facilitate the next major lease
renewal and upgrade cycle for the global commercial IMAX network.

To date, the Company has signed IMAX with Laser agreements with leading, global
exhibitors such as AMC Entertainment Holdings, Inc. ("AMC"), Cineworld Group PLC
("Cineworld"), CGV Holdings Limited ("CGV") and Les Cinémas Pathé Gaumont
("Pathé") (among others) which includes new theaters, upgrades to existing IMAX
theaters, and upgrades to existing backlog arrangements. As at June 30, 2020,
141 IMAX with Laser systems have been installed, and the Company's backlog
included 154 new IMAX with Laser systems and 94 upgrades to IMAX with Laser
systems.

The Company is also experimenting with new technologies and new content as a way
to deepen consumer engagement and brand loyalty, which includes curating unique,
differentiated alternative content to be exhibited in IMAX theaters,
particularly during those periods when Hollywood blockbuster film content is not
available. In 2019, the Company piloted filmed events including Anima, a
one-night only event featuring music from Radiohead's Thom Yorke, Soundgarden:
Live from the Artist's Den: The IMAX Experience, and the Kanye West film Jesus
is King: The IMAX Experience in select IMAX theaters.

IMPACT OF COVID-19 PANDEMIC



In late-January 2020, in response to the public health risks associated with the
novel coronavirus and the disease that it causes ("COVID-19") the Chinese
government directed exhibitors in China to temporarily close more than 70,000
movie theaters, including all of the approximately 700 IMAX theaters in mainland
China. On March 11, 2020, due to the worsening public health crisis associated
with the novel coronavirus, COVID-19 was characterized as a pandemic by the
World Health Organization, and in the following weeks, local, state and national
governments instituted stay-at-home orders and restrictions on large public
gatherings which caused movie theaters in countries around the world to
temporarily close, including substantially all of the IMAX theaters in those
countries. As a result of the theater closures, Hollywood and Chinese movie
studios have postponed the theatrical release of multiple films, including many
scheduled to be shown in IMAX theaters, while other films have been released
directly to streaming platforms. As of the date of this report, stay-at-home
orders have been lifted in many countries and movie theaters are gradually
reopening with reduced capacities, physical distancing requirements, and other
safety measures. Subsequent to June 30, 2020, approximately 40% of the theaters
in the IMAX commercial multiplex network have begun to report gross box office
("GBO") results in July. These theaters span across 40 countries and include the
Domestic, Greater China and Rest of World markets.

The repercussions of the COVID-19 global pandemic have resulted in a significant
decrease in the Company's revenues, earnings and operating cash flows during the
three and six months ended June 30, 2020 as GBO results declined significantly,
the installation of certain theater systems was delayed, and maintenance
services were generally suspended. During the time period when a significant
number of theaters in the IMAX network are closed, the Company has and will
continue to experience a significant decline in earnings and operating cash
flows as it is generating significantly lower than normal levels of GBO-based
revenue from its joint revenue sharing arrangements and digital remastering
services, it is unable to provide normal maintenance services to any of the
theaters that remain closed, and while some installation activity is continuing,
certain theater system installations have, and may continue to be delayed. In
addition, the Company has experienced and may continue to experience delays in
collecting payments due under existing theater sale or lease arrangements from
its exhibitor partners who are now facing financial difficulties as a result of
the theater closures.

The Company may continue to be significantly impacted by the COVID-19 global
pandemic even after some or all theaters are reopened. The global economic
impact of COVID-19 has led to record levels of unemployment in certain
countries, which has led to, and may continue to result in, lower consumer
spending. The timing and extent of a recovery of consumer behavior and
willingness to spend discretionary income on movie-going may delay the Company's
ability to generate significant GBO-based revenue until such time as consumer
behavior normalizes and consumer spending recovers.

In response to uncertainties associated with the COVID-19 pandemic, the Company
has taken and is continuing to take significant steps to preserve cash by
eliminating non-essential costs, reducing employee hours and deferring all
non-essential capital expenditures to minimum levels. The Company has also
implemented an active cash management process, which, among other things,
requires senior management approval of all outgoing payments. In addition, in
the first quarter of 2020, the Company drew down the $280.0 million in available
borrowing capacity under its credit facility, which was then amended in June
2020 to, among other things, suspend the senior secured net leverage ratio
financial covenant in the underlying credit agreement through the first quarter
of 2021. (See Note 7 of Notes to Condensed Consolidated Financial Statements.)
Furthermore, the Company has applied for wage subsidies,

                                       46

--------------------------------------------------------------------------------


tax credits and other financial support under the newly enacted COVID-19 relief
legislation in the countries in which it operates. The Company received
approximately $2.2 million in July 2020 under the Canada Emergency Wage Subsidy
program and expects to receive $1.0 million under the U.S. CARES Act, both of
which were recognized in the second quarter of 2020 as reductions to selling,
general and administrative expenses ($2.9 million) and costs and expenses
applicable to revenues ($0.3 million) in the Condensed Consolidated Statements
of Operations. The Company will continue to review and apply for additional
subsidies and credits for the remaining terms of these programs, where
applicable.

Consistent with the first quarter of 2020, the Company performed a quantitative
goodwill impairment test taking into account the latest available information
and determined that its goodwill was not impaired as of June 30, 2020. As of
that date, the Company's total Goodwill was $39.0 million, of which $19.0
million relates to the IMAX Systems reporting unit, $13.6 million relates to the
Joint Revenue Sharing Arrangement reporting unit, and $6.4 million relates to
the IMAX Maintenance reporting unit. The impairment test was performed on a
reporting unit level by comparing each unit's carrying value, including
goodwill, to its fair value. The fair value of each reporting unit was assessed
using a discounted cash flow model based on management's estimated long-term
projections, against which various sensitivity analyses were performed. These
estimates and the likelihood of future changes in these estimates depend on a
number of underlying variables and a range of possible outcomes. Actual results
may materially differ from management's estimates, especially due to the
uncertainties associated with the COVID-19 pandemic. (See Note 1 of Notes to
Condensed Consolidated Financial Statements.)

If business conditions deteriorate further, or should they remain depressed for
a prolonged period of time, management's estimates of operating results and
future cash flows for the IMAX Systems and Joint Revenue Sharing Arrangements
reporting units may be insufficient to support the goodwill assigned to them,
thus requiring impairment charges. The Company will continue to evaluate the
recoverability of goodwill at the reporting unit level on an annual basis as of
the beginning of its fourth fiscal quarter and whenever events or changes in
circumstances indicate there may be a potential impairment. Estimates related to
future expected credit losses and deferred tax assets could also be materially
impacted by changes in estimates in the future. (See Notes 1, 4 and 11 of Notes
to Condensed Consolidated Financial Statements.)

See "Risk Factors - The Company has experienced a significant decrease in its
revenues, earnings and cash flows due to the COVID-19 global pandemic and its
business, financial condition and results of operations may continue to be
significantly harmed in future reporting periods" in Part II, Item 1A of this
Form 10-Q.

SOURCES OF REVENUE

For the purposes of MD&A the Company has organized its reportable segments into
the following four categories: (i) IMAX Technology Network; (ii) IMAX Technology
Sales and Maintenance; (iii) New Business Initiatives; and (iv) Film
Distribution and Post-production. Within these categories are the Company's
following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing
Arrangements; (iii) IMAX Systems; (iv) IMAX Maintenance; (v) Other Theater
Business; (vi) New Business Initiatives; (vii) Film Distribution; and (viii)
Film Post-production. In the first quarter of 2020, the Company updated certain
account names within Revenues and Costs and Expenses Applicable to Revenues in
its Condensed Consolidated Statements of Operations to better describe the
nature of its revenue-generating activities and related costs. For additional
details regarding the Company's sources of revenue, refer to its 2019 Form 10-K
for the year ended December 31, 2019 (the "2019 Form 10-K").

IMAX Technology Network

The IMAX Technology Network earns revenue based on contingent box office receipts and includes the IMAX DMR segment and contingent rent from the Joint Revenue Sharing Arrangement ("JRSA") segment, as described in more detail below.

IMAX DMR



The Company has developed IMAX DMR, a proprietary technology that digitally
remasters Hollywood films into IMAX formats. In a typical IMAX DMR film
arrangement, the Company receives a percentage of the box office receipts from a
movie studio in exchange for converting a commercial film into IMAX DMR format
and distributing it through the IMAX network. In recent years, the percentage of
gross box office receipts earned in IMAX DMR arrangements has averaged
approximately 12.5%, except for within Greater China, where the Company receives
a lower percentage of net box office receipts for certain Hollywood films.

IMAX DMR digitally enhances the image resolution of motion picture films for
projection on IMAX screens while maintaining or enhancing the visual clarity and
sound quality to levels for which The IMAX Experience is known. In addition, the
original soundtrack of a film to be exhibited in IMAX theaters is remastered for
IMAX digital sound systems in connection with the IMAX DMR release of the film.
Unlike the soundtracks played in conventional theaters, IMAX remastered
soundtracks are uncompressed and full fidelity.

                                       47

--------------------------------------------------------------------------------


IMAX sound systems use proprietary loudspeaker systems and proprietary surround
sound configurations that ensure every theater seat is in an optimal listening
position.

IMAX films also benefit from enhancements made by individual filmmakers
exclusively for the IMAX release of the film: collectively, the Company refers
to those enhancements as "IMAX DNA". Filmmakers and movie studios have sought
IMAX-specific enhancements in recent years to generate interest in and
excitement for their films. Such enhancements include shooting films with IMAX
cameras to increase the audience's immersion in the film and taking advantage of
the unique dimensions of the IMAX screen by projecting the film in a larger
aspect ratio that delivers up to 26% more image onto a movie screen. Avengers:
Endgame, the highest-grossing film in history, released in April 2019, was shot
entirely using IMAX cameras. In addition, in 2020, Universal Pictures' 1917 was
released with select scenes specifically formatted for IMAX screens.

The Company believes that growth in international box office remains an
important driver of growth for the Company. To support continued growth in
international markets, the Company has sought to bolster its international film
strategy, supplementing the Company's film slate of Hollywood DMR titles with
appealing local IMAX DMR releases in select markets, particularly in
China. During 2019, 18 local language IMAX DMR films were released to the IMAX
network, including 14 in China and one in each of Japan, South Korea, India and
Russia. The blockbuster Ne Zha: The IMAX Experience was released in China in
July 2019 and was the Company's first Chinese animated local language film
title. During the six months ended June 30, 2020, two local language IMAX DMR
films were released to the IMAX network, one in Russia and one in Japan. The
Company expects to announce additional local language IMAX DMR films to be
released to the IMAX network in the remainder of 2020 and beyond.

The Company remains in active negotiations with all of the major Hollywood
studios for additional films to fill out its short and long-term film slate for
the IMAX network. However, as a result of the theater closures associated with
the COVID-19 global pandemic, Hollywood and Chinese movie studios have postponed
the theatrical release of multiple films, including many scheduled to be shown
in IMAX theaters, while other films have been released directly to streaming
platforms. Accordingly, the anticipated release dates for any films are
uncertain.

Joint Revenue Sharing Arrangements - Contingent Rent



The JRSA segment provides IMAX theater systems to exhibitors through joint
revenue sharing arrangements. Under the traditional form of these arrangements,
IMAX provides the IMAX projection and sound system under a long-term lease in
which the Company assumes the majority of the equipment and installation costs.
In exchange for its upfront investment, the Company earns rent based on a
percentage of contingent box office receipts and, in some cases, concession
revenues, rather than requiring the customer to pay a fixed upfront fee or
annual minimum payments. Rental payments from the customer are required
throughout the term of the arrangement and are due either monthly or quarterly.
The Company retains title to the IMAX Theater System equipment components
throughout the lease term, and the equipment is returned to the Company at the
conclusion of the arrangement.

Under certain other joint revenue sharing arrangements, knowns as hybrid
arrangements, the customer is responsible for making fixed upfront payments
prior to the delivery and installation of the IMAX Theater System in an amount
that is typically half of what the Company would receive from a typical sale
transaction. As with a traditional joint revenue sharing arrangement, the
customer also pays the Company a percentage of contingent box office receipts
over the term of the arrangement, although this percentage is typically half
that of a traditional joint revenue sharing arrangement. For hybrid joint
revenue sharing arrangements that take the form of a lease, the contingent rent
is reported within the IMAX Technology Network, while the fixed upfront payment
is recorded as revenue within IMAX Technology Sales and Maintenance, as
discussed below. For hybrid joint revenue sharing arrangements that take the
form of a sale, see the discussion below under IMAX Technology Sales and
Maintenance.

Under most joint revenue sharing arrangements (both traditional and hybrid), the
initial non-cancellable term is 10 years or longer and is renewable by the
customer for one to two additional terms of between three to five years. The
Company has the right to remove the equipment for non-payment or other defaults
by the customer. The contracts are non-cancellable by the customer unless the
Company fails to perform its obligations.

The revenue earned from customers under the Company's joint revenue sharing
arrangements can vary from quarter-to-quarter and year-to-year based on a number
of factors including film performance, the mix of theater system configurations,
the timing of installation of these theater systems, the nature of the
arrangement, the location, size and management of the theater and other factors
specific to individual arrangements.

Joint revenue sharing arrangements also require IMAX to provide maintenance and
extended warranty services to the customer over the term of the lease in
exchange for a separate fixed annual fee. These fees are reported within IMAX
Technology Sales and Maintenance, as discussed below.

                                       48

--------------------------------------------------------------------------------

IMAX Technology Sales and Maintenance



The IMAX Technology Sales and Maintenance category includes results from the
IMAX Systems, IMAX Maintenance, and Other Theater Business segments, as well as
certain revenues from the JRSA segment, as described in more detail below.

IMAX Systems



The IMAX Systems segment provides IMAX Theater Systems to exhibitors through
sale arrangements or long-term lease arrangements that for accounting purposes
are classified as sales-type leases. Under these arrangements, in exchange for
providing the IMAX Theater System, the Company earns initial fees and ongoing
consideration (which can include fixed annual minimum payments and contingent
fees in excess of the minimum payments), as well as maintenance and extended
warranty fees (see "IMAX Maintenance" below). The initial fees vary depending on
the system configuration and location of the theater. Initial fees are paid to
the Company in installments between the time of signing the arrangement and the
time of system installation, which is when the total of these fees, in addition
to the present value of future annual minimum payments, are recognized as
revenue. Finance income is recognized over the term of a financed sale or
sales-type lease arrangement. In addition, in sale arrangements, an estimate of
the contingent fees that may become due if certain annual minimum box office
receipt thresholds are exceeded, is recorded as revenue in the period when the
sale is recognized and is adjusted in future periods based on actual results and
changes in estimates. Such variable consideration is only recognized on sales
transactions to the extent the Company believes there is not a risk of
significant revenue reversal.

In sale arrangements, title to the IMAX Theater System equipment generally
transfers to the customer. However, in certain instances, the Company retains
title or a security interest in the equipment until the customer has made all
payments required by the agreement or until certain shipment events for the
equipment have occurred. In a sales-type lease arrangement, title to the IMAX
Theater System equipment remains with the Company. The Company has the right to
remove the equipment for non-payment or other defaults by the customer.

The revenue earned from customers under the Company's theater system sales or
lease agreements varies from quarter-to-quarter and year-to-year based on a
number of factors, including the number and mix of theater system configurations
sold or leased, the timing of installation of the theater systems, the nature of
the arrangement and other factors specific to individual contracts.

Joint Revenue Sharing Arrangements - Fixed Fees



Under certain joint revenue sharing arrangements, known as hybrid arrangements,
the customer is responsible for making fixed upfront payments prior to the
delivery and installation of the IMAX Theater System in an amount that is
typically half of what the Company would receive from a typical sale
transaction. For hybrid joint revenue sharing arrangements that take the form of
a lease, the contingent rent is reported within the IMAX Technology Network, as
discussed above, while the fixed upfront payment is reported within IMAX
Technology Sales and Maintenance.

IMAX Maintenance



For all IMAX theaters, theater owners or operators are also responsible for
paying the Company an annual maintenance and extended warranty fee. Under these
arrangements, the Company provides proactive and emergency maintenance services
to every theater in its network to ensure that each presentation is up to the
highest IMAX quality standard. Annual maintenance fees are paid throughout the
duration of the term of the theater agreements.

Other Theater Business

The Other Theater Business segment principally includes after-market sales of IMAX projection system parts and 3D glasses.


                                       49

--------------------------------------------------------------------------------

New Business Initiatives



The New Business Initiatives segment includes activities related to the
exploration of new lines of business and new initiatives outside of the
Company's core business, which seek to leverage its proprietary, innovative
technologies, its leadership position in the entertainment technology space and
its unique relationship with content creators. Such new business initiatives
currently include IMAX Enhanced and Connected Theaters, as discussed below.

IMAX Enhanced



In September 2018, the Company announced a new home entertainment licensing and
certification program called IMAX Enhanced. This initiative was launched along
with audio leader DTS (an Xperi subsidiary), capitalizing on the companies'
decades of combined expertise in image and sound science. The certification
program combines high-end consumer electronics products with IMAX digitally
remastered 4K high dynamic range (HDR) content and DTS audio technologies to
offer consumers immersive sight and sound experiences for the home.

To be accepted into the program, leading consumer electronics manufacturers must
design 4K HDR televisions, A/V receivers, sound systems and other home theater
equipment to meet a carefully prescribed set of audio and video performance
standards, set by a certification committee of IMAX and DTS engineers and some
of Hollywood's leading technical specialists.

The program will digitally remaster content to produce more vibrant colors, greater contrast and sharper clarity, and will also deliver an IMAX signature sound experience.



IMAX Enhanced Program device partners include Sony Electronics, Denon, Marantz,
Pioneer, and TCL (among others), as well as movie studio partners including Sony
Pictures and Paramount Pictures.

Connected Theaters





The Company is currently exploring new technologies and forms of content as a
way to deepen consumer engagement and brand loyalty, including new technologies
to further connect the IMAX network and to facilitate bringing more unique
content, including live events, to IMAX theater audiences. The Company believes
such additional connectivity can provide more innovative content to the IMAX
network and in turn permit the Company to engage audiences in new ways.

The Company continues to believe that the IMAX network serves as a valuable platform to launch and distribute original content, especially during periods between peak and off-peak seasons, known as shoulder periods.

Film Distribution and Post-production



Through the Film Distribution segment, the Company licenses film content and
distributes large-format films, primarily for its institutional theater
partners. The Company generally distributes films which it produces or for which
it has acquired distribution rights from independent producers. The Company
receives either a percentage of the theater box office receipts or a fixed
amount as a distribution fee. The Company expects to release the IMAX original
production, Asteroid Hunters, later in 2020.

The Film Post-production segment provides film post-production and quality control services for large-format films (whether produced by IMAX or third parties), and digital post-production services.


                                       50

--------------------------------------------------------------------------------



IMAX NETWORK AND BACKLOG

IMAX Network

The following table provides detailed information about the IMAX network by type and geographic location as at June 30, 2020 and 2019:





                                                          June 30, 2020                                                        June 30, 2019
                                  Commercial       Commercial                                          Commercial       Commercial
                                  Multiplex        Destination       Institutional        Total        Multiplex        Destination       Institutional        Total
United States                             371                 4                  30           405              367                 4                  33           404
Canada                                     39                 2                   7            48               39                 2                   7            48
Greater China(1)                          699                 -                  15           714              648                 -                  15           663
Western Europe                            114                 4                   7           125              105                 5                  10           120
Asia (excluding Greater China)            122                 2                   2           126              112                 2                   2           116
Russia & the CIS                           68                 -                   -            68               65                 -                   -            65
Latin America(2)                           50                 1                  12            63               48                 1                  12            61
Rest of the World                          64                 -                   2            66               61                 1                   2            64
Total                                   1,527                13                  75         1,615            1,445                15                  81         1,541



(1) Greater China includes China, Hong Kong, Taiwan and Macau.

(2) Latin America includes South America, Central America and Mexico.




The Company currently believes that over time its commercial multiplex network
could grow to approximately 3,318 IMAX theaters worldwide from the 1,527
operating as at June 30, 2020. The Company believes that the majority of its
future growth will come from international markets. As at June 30, 2020, 72.0%
of IMAX Theater Systems in operation were located within international markets
(defined as all countries other than the United States and Canada), up from
70.7% as at June 30, 2019. Revenues and gross box office derived from
international markets continue to exceed revenues and gross box office from the
United States and Canada. Risks associated with the Company's international
business are outlined in "Risk Factors - The Company conducts business
internationally, which exposes it to uncertainties and risks that could
negatively affect its operations, sales and future growth prospects" in Item 1A
of the Company's 2019 Form 10-K.

Greater China is the Company's largest market, measured by revenues, with
approximately 31% of overall revenues generated from its Greater China
operations in the year ended December 31, 2019. As at June 30, 2020, the Company
had 714 theaters operating in Greater China with an additional 271 theaters in
backlog that are scheduled to be installed by 2023. The Company's backlog in
Greater China represents 48.5% of the Company's current backlog including
upgrades. The Company's largest single international partnership is in China
with Wanda Film ("Wanda"). Wanda's total commitment to the Company is for 359
IMAX Theater Systems in Greater China (of which 354 IMAX Theater Systems are
under the parties' joint revenue sharing arrangement). See "Risk Factors - The
Company faces risks in connection with the continued expansion of its business
in China" in Item 1A of the Company's 2019 Form 10-K.

See "Management's Discussion and Analysis of Financial Condition and Results of
Operations - Impact of COVID-19 Pandemic" in Item 2 of this Form 10-Q and "Risk
Factors - The Company has experienced a significant decrease in its revenues,
earnings and cash flows due to the COVID-19 global pandemic and its business,
financial condition and results of operations may continue to be significantly
harmed in future reporting periods" in Part II, Item 1A of this Form 10-Q.

                                       51

--------------------------------------------------------------------------------


The following tables provide detailed information about the Commercial Multiplex
theaters in operation within the IMAX network by arrangement type and geographic
location as at June 30, 2020 and 2019:



                                                                        June 30, 2020
                                                        Commercial

Multiplex Theaters in IMAX Network


                                            Traditional          Hybrid     

Sale / Sales-


                                               JRSA               JRSA            type Lease              Total
Domestic Total (United States & Canada)              278                5                   127                 410

International:


Greater China                                        358              104                   237                 699
Asia (excluding Greater China)                        33                2                    87                 122
Western Europe                                        45               27                    42                 114
Russia & the CIS                                       -                -                    68                  68
Latin America                                          2                -                    48                  50
Rest of the World                                     14                -                    50                  64
International Total                                  452              133                   532               1,117
Worldwide Total(1)                                   730              138                   659               1,527

                                                                        June 30, 2019
                                                        Commercial

Multiplex Theaters in IMAX Network


                                            Traditional          Hybrid     

Sale / Sales-


                                               JRSA               JRSA            type Lease              Total
Domestic Total (United States & Canada)              275                5                   126                 406

International:


Greater China                                        328              101                   219                 648
Asia (excluding Greater China)                        34                1                    77                 112
Western Europe                                        41               26                    38                 105
Russia & the CIS                                       -                -                    65                  65
Latin America                                          1                -                    47                  48
Rest of the World                                     14                -                    47                  61
International Total                                  418              128                   493               1,039
Worldwide Total(1)                                   693              133                   619               1,445



(1) Period-to-period changes in tables above are reported net of the effect of


    permanently closed theaters.




As at June 30, 2020, 278 (2019 - 275) of the 730 (2019 - 693) theaters under
traditional joint revenue sharing arrangements in operation, or 38.1% (2019 -
39.7%), were located in the United States and Canada, with the remaining 452
(2019 - 418) or 61.9% (2019 - 60.3%) of theaters being located in international
markets.


                                       52

--------------------------------------------------------------------------------

Sales Backlog

The following table provides detailed information about the Company's sales backlog as at June 30, 2020 and 2019:





                                                       June 30, 2020                                                       June 30, 2019
                                       Number of                        Dollar Value                       Number of                        Dollar Value
                                        Systems                        (in thousands)                       Systems                        (in thousands)
                                 New            Upgrade             New            Upgrade           New            Upgrade             New            Upgrade
Sales and sales-type lease
arrangements                       179                11         $ 207,544         $ 14,518            179                 3         $ 227,676         $  4,421
Hybrid JRSA                        147                 7           106,400            5,560            145                 9           105,884            7,110
Traditional JRSA                   133   (1)          82   (1)         300   (2)      5,500   (2)      167   (1)         109   (1)         400   (2)      7,300   (2)
                                   459               100         $ 314,244         $ 25,578            491               121         $ 333,960         $ 18,831

(1) Includes 46 IMAX Theater Systems (2019 - 60) where the customer has the

option to convert from a joint revenue sharing arrangement to a sales

arrangement.

(2) Reflects contractual upfront payments. Future contingent payments are not

reflected as these are based on negotiated shares of box office results.




The number of IMAX Theater Systems in the backlog reflects the minimum number of
commitments under signed contracts. The dollar value fluctuates depending on the
number of new arrangements signed from year-to-year, which adds to backlog and
the installation and acceptance of IMAX Theater Systems and the settlement of
contracts, both of which reduce backlog. Sales backlog typically represents the
fixed contracted revenue under signed IMAX Theater System sale and lease
agreements that the Company believes will be recognized as revenue upon
installation and acceptance of the associated system, as well as an estimate of
variable consideration, however it excludes amounts allocated to maintenance and
extended warranty revenues. The value of sales backlog does not include revenue
from theaters in which the Company has an equity interest, operating leases and
long-term conditional theater commitments. Theaters under joint revenue sharing
arrangements do not usually have dollar value in backlog, although certain IMAX
Theater Systems under joint revenue sharing arrangements provide for contracted
upfront payments and therefore carry a backlog value based on those payments.
The Company believes that the contractual obligations for IMAX Theater System
installations that are listed in sales backlog are valid and binding
commitments.

From time to time, in the normal course of its business, the Company will have
customers who are unable to proceed with an IMAX Theater System installation for
a variety of reasons, including the inability to obtain certain consents,
approvals or financing. Once the determination is made that the customer will
not proceed with installation, the agreement with the customer is terminated or
amended. If the agreement is terminated, once the Company and the customer are
released from all their future obligations under the agreement, all or a portion
of the initial rents or fees that the customer previously made to the Company
are recognized as revenue.

Certain of the Company's contracts contain options for the customer to elect to
upgrade system type during the term or to alter the contract structure (for
example, from a joint revenue sharing arrangement to a sale) after signing but
before installation. Current backlog information reflects all known elections.



                                       53

--------------------------------------------------------------------------------


The following tables provide detailed information about the Company's sales
backlog by arrangement type and geographic location as at June 30, 2020 and
2019:



                                                                    June 30, 2020
                                                             IMAX Theater System Backlog
                                           Traditional           Hybrid
                                               JRSA               JRSA         Sale / Lease        Total
Domestic Total (United States & Canada)              124                 3                11            138

International:


Greater China                                         67               121                83            271
Asia (excluding Greater China)                         5                15                32             52
Western Europe                                        12                13                 7             32
Russia & the CIS                                       -                 1                15             16
Latin America                                          3                 -                10             13
Rest of the World                                      4                 1                32             37
International Total                                   91               151               179            421
Worldwide Total                                      215               154               190            559   (1)

                                                                    June 30, 2019
                                                             IMAX Theater System Backlog
                                           Traditional           Hybrid
                                               JRSA               JRSA         Sale / Lease        Total
Domestic Total (United States & Canada)              156                 3                 8            167

International:


Greater China                                         86               135                80            301
Asia (excluding Greater China)                        12                 -                38             50
Western Europe                                        16                16                 9             41
Russia & the CIS                                       -                 -                14             14
Latin America                                          1                 -                10             11
Rest of the World                                      5                 -                23             28
International Total                                  120               151               174            445
Worldwide Total                                      276               154               182            612   (2)



(1) Includes 154 new IMAX with Laser projection system configurations and 94

upgrades of existing locations to IMAX with Laser projection system

configurations.

(2) Includes 139 new IMAX with Laser projection system configurations and 118

upgrades of existing locations to IMAX with Laser projection system

configurations.

Approximately 75.3% of IMAX Theater System arrangements in backlog as at June 30, 2020 are scheduled to be installed in international markets (2019 - 72.7%).



See "Management's Discussion and Analysis of Financial Condition and Results of
Operations - Impact of COVID-19 Pandemic" in Item 2 of this Form 10-Q and "Risk
Factors - The Company has experienced a significant decrease in its revenues,
earnings and cash flows due to the COVID-19 global pandemic and its business,
financial condition and results of operations may continue to be significantly
harmed in future reporting periods" in Part II, Item 1A of this Form 10-Q.

                                       54

--------------------------------------------------------------------------------

Signings and Installations



The following tables provide detailed information about IMAX Theater System
signings and installations for the three and six months ended June 30, 2020 and
2019:



                                               For the Three Months Ended                 For the Six Months Ended
                                                        June 30,                                  June 30,
                                               2020                   2019               2020                   2019
Theater System Signings:
New IMAX Theater Systems
Sales and sales-type lease arrangements               12                      7                 14                     16
Hybrid joint revenue sharing lease
arrangements                                          17                     45                 17                     48
Traditional joint revenue sharing
arrangements                                           -                      2                  2                      4
Total new IMAX Theater Systems                        29                     54                 33                     68
Upgrades of IMAX Theater Systems                       -                     19                 11                     28
Total IMAX Theater System signings                    29                     73                 44                     96

                                               For the Three Months Ended                 For the Six Months Ended
                                                        June 30,                                  June 30,
                                               2020                   2019               2020                   2019
Theater System Installations:
New IMAX Theater Systems
Sales and sales-type lease arrangements                2                      9                  4                     15
Hybrid joint revenue sharing lease
arrangements                                           1                      5                  2                      9
Traditional joint revenue sharing
arrangements                                           -                     13                  2                     17
Total new IMAX Theater Systems                         3                     27                  8                     41
Upgrades of IMAX Theater Systems                       -                      8                  7                     11
Total IMAX Theater System installations                3                     35                 15                     52


See "Management's Discussion and Analysis of Financial Condition and Results of
Operations - Impact of COVID-19 Pandemic" in Item 2 of this Form 10-Q and "Risk
Factors - The Company has experienced a significant decrease in its revenues,
earnings and cash flows due to the COVID-19 global pandemic and its business,
financial condition and results of operations may continue to be significantly
harmed in future reporting periods" in Part II, Item 1A of this Form 10-Q.


                                       55

--------------------------------------------------------------------------------

RESULTS OF OPERATIONS

The Company's business and future prospects are evaluated by Richard L. Gelfond, its Chief Executive Officer ("CEO"), using a variety of financial and operational metrics including:

• the signing, installation and financial performance of theater system

arrangements, particularly joint revenue sharing arrangements and those


     involving laser-based projection systems;



• film performance and the securing of new film projects, particularly IMAX DMR


     films;



• the continuing ability to invest in and improve the Company's technology to

enhance the differentiation of The IMAX Experience, versus other cinematic


     experiences;



• revenues and gross margins from the Company's segments, as discussed below;






  • consolidated earnings from operations, as adjusted for unusual items;



• the overall execution, reliability and consumer acceptance of The IMAX


     Experience;




  • the success of new business initiatives; and




  • short- and long-term cash flow projections.


The CEO is the Company's Chief Operating Decision Maker ("CODM"), as such term
is defined under U.S. GAAP. The CODM, along with other members of management,
assess segment performance based on segment revenues and gross margins. Selling,
general and administrative expenses, research and development costs, the
amortization of intangibles, provisions for (recoveries of) current expected
credit losses, certain write-downs, interest income, interest expense and income
tax (expense) benefit are not allocated to the segments.

The Company has organized its reportable segments into the following four
categories: (i) IMAX Technology Network; (ii) IMAX Technology Sales and
Maintenance; (iii) New Business Initiatives; and (iv) Film Distribution and
Post-production. Within these categories are the Company's following reportable
segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX
Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) New Business
Initiatives; (vii) Film Distribution; and (viii) Film Post-production, each of
which are described above under "Sources of Revenue." This categorization is
consistent with how the CODM reviews the financial performance of the Company
and makes strategic decisions regarding resource allocation and investments to
meet long-term business goals. Management believes that a discussion and
analysis based on the four categories listed above is significantly more
relevant and useful to readers, as the Company's consolidated statements of
operations captions combine results from several segments.


                                       56

--------------------------------------------------------------------------------

Results of Operations for the Three Months Ended June 30, 2020 and June 30, 2019



For the three months ended June 30, 2020, the Company reported a net loss
attributable to common shareholders of $(26.0) million, or $(0.44) per basic and
diluted share, as compared to net income attributable to common shareholders of
$11.4 million, or $0.19 per basic and diluted share, for the same period in
2019. For the three months ended June 30, 2020, the Company reported an adjusted
net loss attributable to common shareholders* of $(26.1) million, or $(0.44) per
basic and diluted share*, as compared to adjusted net income attributable to
common shareholders* of $19.7 million, or $0.32 per diluted share*, for the same
period in 2019.

The following table sets forth the breakdown of revenue and (margin loss) gross
margin by category and reportable segment for the three months ended June 30,
2020 and 2019:



(In thousands of U.S. dollars)                     Revenue                (Margin Loss) Gross Margin
                                             2020          2019            2020                2019
IMAX Technology Network
IMAX DMR                                   $     546     $  39,293     $         (30 )     $      23,961
Joint revenue sharing arrangements,
contingent rent(3)                              (137 )      25,540            (6,501 )            19,318
                                                 409        64,833            (6,531 )            43,279
IMAX Technology Sales and Maintenance
IMAX Systems (1)                               4,549        16,501             2,650               8,019
Joint revenue sharing arrangements,
fixed fees                                       369         2,548                48                 870
IMAX Maintenance                                   -        13,207            (1,908 )             5,640
Other Theater Business (2)(4)                   (309 )       2,580              (564 )               841
                                               4,609        34,836               226              15,370
New Business Initiatives                         632           478               512                 281

Film Distribution and Post-production 3,182 3,601


  (1,396 )               458
Sub-total                                      8,832       103,748            (7,189 )            59,388
Other                                             23         1,049              (499 )               165
Total                                      $   8,855     $ 104,797     $      (7,688 )     $      59,553

(1) Includes initial upfront payments and the present value of fixed minimum

payments from sale and sales-type lease arrangements of IMAX Theater Systems,

and the present value of estimated variable consideration from sales of IMAX

Theater Systems. To a lesser extent, also includes finance income associated

with these revenue streams.

(2) Principally includes after-market sales of IMAX projection system parts and

3D glasses.




(3) The Company is reporting negative revenue due to the continued amortization
of lessee incentives that are typically netted against lease revenues, which are
abnormally low in the period due to the COVID-19 global pandemic, as discussed
in Note 2 of Notes to Condensed Consolidated Financial Statements.

(4) The Company is reporting negative revenue due to an adjustment to prior period revenue.

* See "Non-GAAP Financial Measures" below for a description of this non-GAAP

financial measure and a reconciliation to the most comparable GAAP amount.




                                       57

--------------------------------------------------------------------------------

Revenues and Gross Margin



Due to the COVID-19 global pandemic, substantially all of the theaters in the
IMAX network were closed in the second quarter of 2020. As a result, the
Company's results of operations for the period materially declined when compared
to the prior year. For the three months ended June 30, 2020, revenues and gross
margin decreased by $95.9 million (92%) and $67.2 million (113%), respectively,
when compared to the same period in 2019.

IMAX Technology Network



IMAX Technology Network results are influenced by the level of commercial
success and box office performance of the films released to the network, as well
as other factors including the timing of the films released, the length of the
theatrical distribution window, the take rates under the Company's DMR and joint
revenue sharing arrangements and the level of marketing spend associated with
the films released in the period. Other factors impacting IMAX Technology
Network results include fluctuations in the value of foreign currencies versus
the U.S. dollar and potential currency devaluations.

For the three months ended June 30, 2020, IMAX Technology Network revenues and
gross margin decreased by $64.4 million (99%) and $49.8 million (115%),
respectively, when compared to the same period in 2019. See below for separate
discussions of IMAX DMR and JRSA contingent rent results for the period.

IMAX DMR



Due to the COVID-19 global pandemic, substantially all of the theaters in the
IMAX network were closed in the second quarter of 2020. As a result, for the
three months ended June 30, 2020, IMAX DMR revenues and gross margin decreased
by $38.7 million (99%) and $24.0 million (100%), respectively, when compared to
the same period in 2019. These decreases are due to a $362.3 million (99%)
reduction in GBO receipts generated by IMAX DMR films in the second quarter of
2020 as a result of the COVID-19 theater closures. In the second quarter of
2020, GBO was generated by the exhibition of one new film as compared to 19
films (15 new and 4 carryovers) exhibited in the second quarter of 2019.

In addition to the level of revenues, IMAX DMR gross margin is also influenced
by the costs associated with the films exhibited in the period, and can vary
from period-to-period, particularly with respect to marketing expenses. For the
three months ended June 30, 2020, marketing expenses related to IMAX DMR films
were $nil, as compared to $9.5 million during the same period of 2019.

Joint Revenue Sharing Arrangements - Contingent Rent



  Due to the COVID-19 global pandemic, substantially all of the theaters in the
IMAX network were closed in the second quarter of 2020. As a result, for the
three months ended June 30, 2020, JRSA contingent rent revenue and gross margin
decreased by $25.7 million (101%) and $25.8 million (134%), respectively, when
compared to the same period in 2019. These decreases are due to an $185.1
million (100%) reduction in GBO generated by theaters under joint revenue
sharing arrangements in the second quarter of 2020 as a result of the COVID-19
theater closures.

In addition to the level of revenues, JRSA margin is also influenced by the
level of costs associated with such arrangements, such as depreciation expense
related to the underlying theater systems and costs incurred to upgrade theater
systems from digital xenon to IMAX with Laser, as well as advertising, marketing
and commission costs primarily for the launch of new theaters. The level of
depreciation expense in a period relative to the prior year is a function of the
growth of the theater network and the mix of theater system configurations in
the network. For the three months ended June 30, 2020, JRSA gross margin
included depreciation expense of $6.2 million, as compared to $5.7 million in
the same period of the prior year as a result of the 5% increase in the number
of theaters operating under joint revenue sharing arrangements. For the three
months ended June 30, 2020, JRSA gross margin includes advertising, marketing
and commission costs of less than $0.1 million, as compared to $0.2 million in
the same period of the prior year.

                                       58

--------------------------------------------------------------------------------

IMAX Technology Sales and Maintenance



The primary drivers of IMAX Technology Sales and Maintenance results are the
number of IMAX Theater Systems installed in a period, and the level of gross
margin percentage earned on each installation, as well as the associated
maintenance contracts that accompany each theater installation. The installation
of IMAX Theater Systems in newly built theaters or multiplexes, which make up a
large portion of the Company's theater system backlog, depends primarily on the
timing of the construction of those projects, which is not under the Company's
control.

The following table provides detailed information about the mix of IMAX Theater System installations for the three months ended June 30, 2020 and 2019:





                                                          For the Three Months Ended June 30,
                                                        2020                                2019
                                             Number of                             Number of
                                              Systems            Revenue            Systems         Revenue
New IMAX Theater Systems - installed and
recognized
Sales and sales-types lease
arrangements(1)                                        2       $     1,731                   9     $  11,664
Joint revenue sharing arrangements -
hybrid                                                 1               356                   5         2,525
Total new IMAX Theater Systems                         3             2,087                  14        14,189

IMAX theater system upgrades - installed
and recognized
Sales and sales-types lease arrangements               -                 -                   1         1,533
Total IMAX Theater Systems installed and
recognized                                             3       $     2,087                  15     $  15,722

(1) The arrangement for the sale of an IMAX Theater System includes fixed upfront

and ongoing consideration, including indexed annual minimum payment increases

over the term of the arrangement, as well as the provision for additional

payments in excess of the minimum agreed payments in situations when the

theater exceeds certain box office thresholds.




The average revenue per IMAX Theater System under sales and sales-type lease
arrangements varies depending upon the number of IMAX Theater System commitments
with a single respective exhibitor, an exhibitor's location and various other
factors. Average revenue per IMAX Theater System under sales and sales-type
lease arrangements was $0.9 million for the three months ended June 30, 2020, as
compared to $1.3 million during the same period of the prior year.

For the three months ended June 30, 2020, IMAX Technology Sales and Maintenance
revenue and gross margin decreased by $30.2 million (87%) and $15.1 million
(99%), respectively, when compared to the same period in the prior year as the
pace of theater system installations slowed significantly and regular
maintenance services were suspended due to the COVID-19 global pandemic. See
below for separate discussions of IMAX Systems and IMAX Maintenance results for
the period.

IMAX Systems

For the three months ended June 30, 2020, IMAX Systems revenue and gross margin
decreased by $12.0 million (72%) and $5.4 million (67%), respectively, when
compared to the same period in the prior year. These decreases are the result of
the twelve fewer IMAX Theater System installations in the current period as the
pace of theater system installations slowed significantly due to the COVID-19
global pandemic.

IMAX Maintenance

For the three months ended June 30, 2020, IMAX Maintenance revenue and gross
margin decreased by $13.2 million (100%) and $7.5 million (134%), respectively,
as regular maintenance services were suspended and the associated revenue was
not recognized during the period due to the COVID-19 global pandemic.

Maintenance margins vary depending on the mix of theater system configurations
in the theater network, volume-pricing related to larger relationships and the
timing and the date(s) of installation and/or service.


                                       59

--------------------------------------------------------------------------------

Film Distribution and Post-production



For the three months ended June 30, 2020, Film Distribution and Post-production
revenue decreased by $0.4 million (12%) and gross margin decreased by $1.9
million, respectively, when compared to the same period in the prior year. The
results for second quarter of 2020 are significantly influenced by a $2.2
million impairment loss recorded in the period to write-down the carrying value
of certain documentary and alternative content film assets due to a decrease in
projected box office totals and related revenues based on management's regular
quarterly recoverability assessments. As of June 30, 2020, following the
recording of these write-downs, the Company's film assets totaled $13.1 million,
which principally consists of documentary and DMR content. The recoverability of
these assets assumes the return to historical levels of box office results as
theaters reopen following the lifting of COVID-19 restrictions. There can be no
assurances that there will not be additional write-downs to the carrying values
of these assets as the Company continues to assess the ongoing impact of the
COVID-19 pandemic. (See Notes 1 and 2 of Notes to Condensed Consolidated
Financial Statements.)

Selling, General and Administrative Expenses



For the three months ended June 30, 2020, Selling, General and Administrative
Expenses decreased by $2.3 million (7%), when compared to the same period in
2019. For the three months ended June 30, 2020, Selling, General and
Administrative Expenses excluding the impact of share-based compensation were
$23.3 million, as compared to $25.6 million in the same period in 2019,
representing a decrease of $2.3 million (9%).

The comparison to the prior year is significantly influenced by COVID-19
government relief that the Company became entitled to receive during the period
under the Canada Emergency Wage Subsidy program and the U.S. CARES Act, of which
$2.9 million was recognized in the second quarter of 2020 as a reduction to
Selling, General and Administrative Expenses. Also impacting the comparison to
the prior period are management's cost control efforts amidst the COVID-19
global pandemic, resulting in lower staff costs, travel, facilities and
marketing related expenses, among others. These factors are partially offset by
an approximate $8.0 million decrease in labor and other costs capitalized to
inventory, film assets, and joint venture theater equipment or allocated to
costs applicable to revenues, due to the idling of the Company's productive
capacity during the COVID-19 global pandemic.

Credit Loss Expense



For the three months ended June 30, 2020, the Company recorded a provision for
current expected credit losses of $1.4 million reflecting a reduction in the
credit quality of its theater and studio related receivable balances, which
management believes is primarily related to the COVID-19 pandemic, as discussed
in Note 2 of Notes to Condensed Consolidated Financial Statements. Management's
judgments regarding expected credit losses are based on the facts available to
management and involve estimates about the future. Due to the unprecedented
nature of the COVID-19 pandemic, its effect on the Company's customers and their
ability to meet their financial obligations to the Company is difficult to
predict. As a result, the Company's judgments and associated estimates of credit
losses may ultimately prove, with the benefit of hindsight, to be incorrect. For
the three months ended June 30, 2019, credit loss expense was $0.9 million. (See
Notes 2 and 3 of Notes to Condensed Consolidated Financial Statements.)

Gain (loss) in fair value of equity securities



In the first quarter of 2019, IMAX China (Hong Kong), Limited, a wholly-owned
subsidiary of IMAX China, entered into a cornerstone investment agreement with
Maoyan Entertainment ("Maoyan") and purchased equity securities for $15.2
million. These equity securities are traded on the Hong Kong Stock Exchange, and
the Company is required to adjust the fair value of the securities each period
to reflect the current market value. This adjustment will fluctuate based on the
closing market price at the end of each period. For the three months ended
June 30, 2020, the fair value of the Company's investment in Maoyan experienced
an unrealized gain of $2.0 million, as compared to an unrealized loss of $4.5
million in the same period of the prior year, which are both recognized in the
Condensed Consolidated Statements of Operations.

Income Taxes



The Company's effective tax benefit rate for the three months ended June 30,
2020, is 25.4% and differs from the Canadian statutory tax rate of 26.2%,
primarily due to permanent book to tax differences, investment and other tax
credits, jurisdictional tax rate differences, management's estimates of
contingent liabilities related to the resolution of various tax examinations and
withholding taxes associated with the reversal of the indefinite reinvestment
assertion for certain foreign subsidiaries, as discussed below.


                                       60

--------------------------------------------------------------------------------


In the first quarter of 2020, management completed a reassessment of its
strategy with respect to the most efficient means of deploying the Company's
capital resources globally. Based on the results of this reassessment,
management concluded that the historical earnings of certain foreign
subsidiaries in excess of amounts required to sustain business operations would
no longer be indefinitely reinvested. As a result, the Company recognized a
deferred tax liability of $19.7 million in the first quarter of 2020 for the
estimated applicable foreign withholding taxes associated with these historical
earnings, which will become payable upon the repatriation of any such earnings.
In the second quarter of 2020, the estimate of the applicable foreign
withholding taxes was reduced by $1.2 million to $18.5 million due to a
reduction in the amount of distributable historical earnings. Cash held outside
of Canada as at June 30, 2020 was $75.0 million (December 31, 2019 - $90.1
million), of which $61.5 million was held in the People's Republic of China
("PRC") (December 31, 2019 - $67.6 million).

For the three months ended June 30, 2020, the Company recorded income tax
benefit of $10.2 million (2019 - tax expense of $5.3 million), which includes
the $1.2 million reduction to the foreign withholding taxes discussed above. In
addition, in the second quarter of 2020, the Company recognized income tax
expense of $0.3 million (2019 - $0.1 million) related to the provision for
uncertain tax positions.



As at June 30, 2020, the Company's Condensed Consolidated Balance Sheets include
net deferred income tax assets of $46.8 million, net of a valuation allowance of
$0.2 million (December 31, 2019 - $23.9 million). As at June 30, 2020, the
Company's Condensed Consolidated Balance Sheets include a deferred income tax
liability of $18.5 million (December 31, 2019 - $nil). During the three months
ended June 30, 2020, deferred tax assets increased by $8.9 million due to losses
recognized in the period. The recoverability of these deferred tax assets is
subject to certain levels of future taxable income and the uncertainties
associated with accounting estimates, as discussed in Note 1 of Notes to
Condensed Consolidated Financial Statements. Based on a review of the projected
future earnings of the Company there was no change in management's estimates of
the recoverability of the Company's deferred tax assets. Should actual results
differ from management's estimates of future taxable income, an increased
valuation allowance may be required.

The Company's Chinese subsidiary had taken a deduction for certain share-based
compensation issued by its parent company in a prior period and had recognized a
related deferred tax asset of $1.4 million (December 31, 2019 - $1.4 million).
Chinese regulatory authorities responsible for capital and exchange controls
will need to review and approve the proposed settlement of these transactions
before they can be completed. There may be a requirement for future investment
of funds into China in order to secure the deduction. Should the Company
proceed, any such future investment would come from existing capital invested in
the IMAX China group of companies being redeployed amongst the IMAX China group
of companies, including the Chinese subsidiary.

Non-Controlling Interests



The Company's Condensed Consolidated Financial Statements primarily include the
non-controlling interest in the net income (loss) of IMAX China, as well as the
impact of non-controlling interests in the activity of its Original Film Fund
subsidiary. For the three months ended June 30, 2020, the net loss attributable
to non-controlling interests of the Company's subsidiaries was $4.1 million
(2019 - net income of $2.4 million).


                                       61

--------------------------------------------------------------------------------

Results of Operations for the Six Months Ended June 30, 2020 and 2019



For the six months ended June 30, 2020, the Company reported a net loss
attributable to common shareholders of $(75.3) million, or $(1.26) per basic and
diluted share, as compared to net income attributable to common shareholders of
$19.7 million, or $0.32 per basic and diluted share, for the same period in
2019. For the six months ended June 30, 2020, the Company reported an adjusted
net loss attributable to common shareholders* of $(54.8) million, or $(0.92) per
basic and diluted share*, as compared to adjusted net income attributable to
common shareholders* of $30.5 million, or $0.50 per diluted share*, for the same
period in 2019.

The following table sets forth the breakdown of revenue and (margin loss) gross
margin by category and reportable segment for the six months ended June 30, 2020
and 2019:



(In thousands of U.S. dollars)                     Revenue                 (Margin Loss) Gross Margin
                                             2020          2019            2020                 2019
IMAX Technology Network
IMAX DMR                                   $  11,175     $  67,243     $       4,413       $       43,736
Joint revenue sharing arrangements,
contingent rent                                5,834        43,584            (8,119 )             31,253
                                              17,009       110,827            (3,706 )             74,989
IMAX Technology Sales and Maintenance
IMAX Systems (1)                              10,237        29,527             5,826               15,071
Joint revenue sharing arrangements,
fixed fees                                     1,139         5,087               227                1,165
IMAX Maintenance                               7,370        26,158            (1,149 )             10,921
Other Theater Business (2)                       954         4,206                46                1,316
                                              19,700        64,978             4,950               28,473
New Business Initiatives                       1,110         1,312               873                  900

Film Distribution and Post-production 5,676 6,263


  (3,331 )                433
Sub-total                                     43,495       183,380            (1,214 )            104,795
Other                                            262         1,615            (1,388 )               (102 )
Total                                      $  43,757     $ 184,995     $      (2,602 )     $      104,693

(1) Includes initial upfront payments and the present value of fixed minimum

payments from sale and sales-type lease arrangements of IMAX Theater Systems,

and the present value of estimated variable consideration from sales of IMAX

Theater Systems. To a lesser extent, also includes finance income associated

with these revenue streams.

(2) Principally includes after-market sales of IMAX projection system parts and


    3D glasses.





* See "Non-GAAP Financial Measures" below for a description of this non-GAAP

financial measure and a reconciliation to the most comparable GAAP amount.




Revenues and Gross Margin

Due to the COVID-19 global pandemic, substantially all of the theaters in the
IMAX network were closed for a significant portion of the six months ended
June 30, 2020, with the theaters in Greater China closed since late-January and
substantially all of the Company's remaining theaters closed since mid-to-late
March. As a result, the Company's results of operations for the six-month period
materially declined versus the prior year. For the six months ended June 30,
2020, revenues and gross margin decreased by $141.2 million (76%) and $107.3
million (102%), respectively, when compared to the same period in 2019.

IMAX Technology Network



IMAX Technology Network results are influenced by the level of commercial
success and box office performance of the films released to the network, as well
as other factors including the timing of the films released, the length of the
theatrical distribution window, the take rates under the Company's DMR and joint
revenue sharing arrangements and the level of marketing spend associated with
the films released in the period. Other factors impacting IMAX Technology
Network results include fluctuations in the value of foreign currencies versus
the U.S. dollar and potential currency devaluations.

                                       62

--------------------------------------------------------------------------------


For the six months ended June 30, 2020, IMAX Technology Network revenues and
gross margin decreased by $93.8 million (85%) and $78.7 million (105%),
respectively, when compared to the same period in 2019. See below for separate
discussions of IMAX DMR and JRSA contingent rent results for the period.

IMAX DMR



Due to the COVID-19 global pandemic, substantially all of the theaters in the
IMAX network were closed for a significant portion of the six months ended
June 30, 2020, with the theaters in Greater China closed since late-January and
substantially all of the Company's remaining theaters closed since mid-to-late
March. As a result, for the six months ended June 30, 2020, IMAX DMR revenues
and gross margin decreased by $56.1 million (83%) and $39.3 million (90%),
respectively, when compared to the same period in 2019. These decreases are due
to a $523.4 million (84%) reduction in GBO generated by IMAX DMR films as a
result of the theater closures. For the six months ended June 30, 2020, GBO was
generated primarily by the exhibition of 14 films (10 new and 4 carryovers), as
compared to 39 films (27 new and 12 carryovers) exhibited in the six months
ended June 30, 2019.

In addition to the level of revenues, IMAX DMR gross margin is also influenced
by the costs associated with the films exhibited in the period, and can vary
from period-to-period, particularly with respect to marketing expenses. For the
six months ended June 30, 2020, marketing expenses related to IMAX DMR films
were $2.4 million, as compared to $13.4 million during the same period of 2019.

Joint Revenue Sharing Arrangements - Contingent Rent



Due to the COVID-19 global pandemic, substantially all of the theaters in the
IMAX network were closed for a significant portion of the six months ended
June 30, 2020, with the theaters in Greater China closed since late-January and
substantially all of the Company's remaining theaters closed since mid-to-late
March. As a result, for the six months ended June 30, 2020, JRSA contingent rent
revenue and gross margin decreased by $37.8 million (87%) and $39.4 million
(126%), respectively, when compared to the same period in 2019. The decreases in
revenue and gross margin are due to a $274.0 million (86%) reduction in GBO
generated by theaters under joint revenue sharing arrangements during the
current period due to the theater closures. As at June 30, 2020, 868 theaters
were operating under joint revenue sharing arrangements, as compared to 826
theaters as at June 30, 2019, an increase of 5%.

In addition to the level of revenues, JRSA margin is also influenced by the
level of costs associated with such arrangements, such as depreciation expense
related to the underlying theater systems and costs incurred to upgrade theater
systems from digital xenon to IMAX with Laser, as well as advertising, marketing
and commission costs primarily for the launch of new theaters. The level of
depreciation expense in a period relative to the prior year is a function of the
growth of the theater network and the mix of theater system configurations in
the network. For the six months ended June 30, 2020, JRSA gross margin included
depreciation expense of $13.2 million, as compared to $11.3 million in the same
period of the prior year as a result of the 5% increase in the number of
theaters operating under joint revenue sharing arrangements. For the six months
ended June 30, 2020, JRSA gross margin includes certain advertising, marketing
and commission costs of $0.6 million, as compared to $0.3 million in the same
period of the prior year.

IMAX Technology Sales and Maintenance



The primary drivers of IMAX Technology Sales and Maintenance results are the
number of IMAX Theater Systems installed in a period, and the level of gross
margin percentage earned on each installation, as well as the associated
maintenance contracts that accompany each theater installation.

The installation of IMAX Theater Systems in newly built theaters or multiplexes,
which make up a large portion of the Company's theater system backlog, depends
primarily on the timing of the construction of those projects, which is not
under the Company's control. The following table provides detailed information
about the mix of IMAX Theater System installations for the six months ended
June 30, 2020 and 2019:

                                       63

--------------------------------------------------------------------------------





                                                         For the Six Months Ended June 30,
                                                        2020                              2019
                                             Number of                           Number of
                                              Systems           Revenue           Systems        Revenue
New IMAX Theater Systems - installed and
recognized
Sales and sales-types lease
arrangements(1)                                        4       $    3,731                15     $  19,942
Joint revenue sharing arrangements -
hybrid                                                 2            1,126                 9         5,064
Total new IMAX Theater Systems                         6            4,857                24        25,006

IMAX theater system upgrades - installed
and recognized
Sales and sales-types lease arrangements               -                -                 2         2,028
Total IMAX Theater Systems installed and
recognized                                             6       $    4,857                26     $  27,034

(1) The arrangement for the sale of an IMAX Theater System includes fixed upfront

and ongoing consideration, including indexed annual minimum payment increases

over the term of the arrangement, as well as the provision for additional

payments in excess of the minimum agreed payments in situations when the

theater exceeds certain box office thresholds.




The average revenue per IMAX Theater System under sales and sales-type lease
arrangements varies depending upon the number of IMAX Theater System commitments
with a single respective exhibitor, an exhibitor's location and various other
factors. Average revenue per IMAX Theater System under sales and sales-type
lease arrangements was $0.9 million during the six months ended June 30, 2020,
compared to $1.3 million during the same period of the prior year.

For the six months ended June 30, 2020, IMAX Technology Sales and Maintenance
revenue and gross margin decreased by $45.3 million (70%) and $23.5 million
(83%), respectively, when compared to the same period in the prior year as the
pace of theater system installations slowed significantly and regular
maintenance services were suspended due to the temporary closure of theaters in
the network due to the public health risks associated with the COVID-19 global
pandemic. See below for separate discussions of IMAX Systems and IMAX
Maintenance results for the period.

IMAX Systems



For the six months ended June 30, 2020, IMAX Systems revenue and gross margin
decreased by $19.3 million (65%) and $9.2 million (61%), respectively, when
compared to the same period in the prior year. These decreases are the result of
20 fewer IMAX Theater System installations in the current period as the pace of
theater system installations slowed significantly due to the COVID-19 global
pandemic.

IMAX Maintenance

For the six months ended June 30, 2020, IMAX Maintenance revenue and gross
margin decreased by $18.8 million (72%) and $12.1 million (111%), respectively,
as regular maintenance services were suspended and the associated revenue was
not recognized during the period when substantially all of the theaters in the
network were temporarily closed due to the COVID-19 global pandemic.

Maintenance margins vary depending on the mix of theater system configurations
in the theater network, volume-pricing related to larger relationships and the
timing and the date(s) of installation and/or service.

Film Distribution and Post-production



For the six months ended June 30, 2020, Film Distribution and Post-production
revenue decreased by $0.6 million (9%) and gross margin decreased by $3.8
million, respectively, when compared to the same period in the prior year. The
results for the current six-month period are significantly influenced by a $4.5
million impairment loss recorded in the period to write-down the carrying value
of certain documentary and alternative content film assets due to a decrease in
projected box office totals and related revenues based on management's regular
quarterly recoverability assessments. As of June 30, 2020, following the
recording of these write-downs, the Company's film assets totaled $13.1 million,
which principally consists of documentary and DMR content. The recoverability of
these assets assumes the return to historical levels of box office results as
theaters reopen following the lifting of COVID-19 restrictions. There can be no
assurances that there will not be additional write-downs to the carrying values
of these assets as the Company continues to assess the ongoing impact of the
COVID-19 pandemic. (See Notes 1 and 2 of Notes to Condensed Consolidated
Financial Statements.)

                                       64

--------------------------------------------------------------------------------

Selling, General and Administrative Expenses



For the six months ended June 30, 2020, Selling, General and Administrative
Expenses decreased by $1.4 million (2%), when compared to the same period in
2019. For the three months ended June 30, 2020, Selling, General and
Administrative Expenses excluding the impact of share-based compensation were
$48.2 million, as compared to $49.4 million in the same period in 2019,
representing a decrease of $1.2 million (2%).

The comparison to the prior year is significantly influenced by COVID-19
government relief that the Company became entitled to receive during the period
under the Canada Emergency Wage Subsidy program and the U.S. CARES Act, of which
$2.9 million was recognized in the second quarter of 2020 as a reduction to
Selling, General and Administrative Expenses. Also impacting the comparison to
the prior period are management's cost control efforts amidst the COVID-19
global pandemic resulting in lower staff costs, travel, facilities and marketing
related expenses, among others. These factors are partially offset by an
approximate $9.0 million decrease in labor and other costs capitalized to
inventory, film assets, and joint venture theater equipment or allocated to
costs applicable to revenues, due to the idling of the Company's productive
capacity during the COVID-19 global pandemic.

Research and Development



A significant portion of the Company's research and development efforts over the
past several years have been focused on IMAX with Laser, the Company's
laser-based projection system, which the Company believes delivers increased
resolution, sharper and brighter images, deeper contrast as well as the widest
range of colors available to filmmakers today.

For the six months ended June 30, 2020, Research and Development expenses increased by $1.1 million (46%), when compared to the same period in the prior year, primarily due to costs associated with the Connected Theaters initiative.



The Company also intends to continue research and development in other areas
considered important to the Company's continued commercial success, including
further improving the reliability of its projectors, certifying more IMAX
cameras, enhancing the Company's image quality, expanding the applicability of
the Company's digital technology in both theater and home entertainment and
improvements to the DMR process.

In addition, the Company has been, and intends to continue, using time and
resources during the theater shutdown caused by the COVID-19 global pandemic to
work on leveraging and developing technologies and systems to help bring
additional interactivity to its theater network, better manage certain of the
Company's internal workflows and better organize and codify certain of the
Company's data.  During previous adverse events and downturns in the cinema
business, the Company fostered many of the innovations that helped enable its
global growth in recent years, including the development of its proprietary DMR
process and the creation of its joint-revenue sharing business model.

Credit Loss Expense



For the six months ended June 30, 2020, the Company recorded a provision for
current expected credit losses of $11.7 million reflecting a reduction in the
credit quality of its theater and studio related receivable balances, which
management believes is primarily related to the COVID-19 pandemic, as discussed
in Note 2 of Notes to Condensed Consolidated Financial Statements. Management's
judgments regarding expected credit losses are based on the facts available to
management and involve estimates about the future. Due to the unprecedented
nature of the COVID-19 pandemic, its effect on the Company's customers and their
ability to meet their financial obligations to the Company is difficult to
predict. As a result, the Company's judgments and associated estimates of credit
losses may ultimately prove, with the benefit of hindsight, to be incorrect. For
the six months ended June 30, 2019, credit loss expense was $1.4 million. (See
Notes 2 and 3 of Notes to Condensed Consolidated Financial Statements.)

Asset Impairments



For the six months ended June 30, 2020, the Company recorded asset impairments
of $1.2 million (2019 - $nil) principally related to write-down of
content-related assets which became impaired in the period. (See Notes 1 and 2
of Notes to Condensed Consolidated Financial Statements.)

Gain (loss) in fair value of equity securities



In the second quarter of 2019, IMAX China (Hong Kong), Limited, a wholly-owned
subsidiary of IMAX China, entered into a cornerstone investment agreement with
Maoyan Entertainment ("Maoyan") and purchased equity securities for $15.2
million. These equity securities are traded on the Hong Kong Stock Exchange, and
the Company is required to adjust the fair value of the securities each period
to reflect the current market value. This adjustment will fluctuate based on the
closing market price at the end of each

                                       65

--------------------------------------------------------------------------------


period. For the six months ended June 30, 2020, the fair value of the Company's
investment in Maoyan experienced an unrealized loss of $2.5 million, as compared
to an unrealized loss of $2.1 million in the same period in the prior year,
which are both recognized in the Condensed Consolidated Statements of
Operations.

Income Taxes



The Company's effective tax rate for the six months ended June 30, 2020 is -6.3%
and differs from the Canadian statutory tax rate of 26.2%, primarily due to
permanent book to tax differences, investment and other tax credits,
jurisdictional tax rate differences, managements estimates of contingent
liabilities related to the resolution of various tax examinations and
withholding taxes associated with the reversal of the indefinite reinvestment
assertion for certain foreign subsidiaries, as discussed below.

In the first quarter of 2020, management completed a reassessment of its
strategy with respect to the most efficient means of deploying the Company's
capital resources globally. Based on the results of this reassessment,
management concluded that the historical earnings of certain foreign
subsidiaries in excess of amounts required to sustain business operations would
no longer be indefinitely reinvested. As a result, the Company recognized a
deferred tax liability of $19.7 million in the first quarter of 2020 for the
estimated applicable foreign withholding taxes associated with these historical
earnings, which will become payable upon the repatriation of any such earnings.
In the second quarter of 2020, the estimate of the applicable foreign
withholding taxes was reduced by $1.2 million to $18.5 million due to a
reduction in the amount of distributable historical earnings. Cash held outside
of Canada as at June 30, 2020 was $75.0 million (December 31, 2019 - $90.1
million), of which $61.5 million was held in the People's Republic of China
("PRC") (December 31, 2019 - $67.6 million).

For the six months ended June 30, 2020, the Company recorded income tax expense
of $5.3 million (2019 - $9.0 million), which includes the $18.5 million foreign
withholding taxes discussed above. In addition, in the six months ended June 30,
2020, the Company recognized income tax expense of $5.1 million (2019 - $0.5
million) related to the provision for uncertain tax positions and an expense of
$0.7 million (2019 - $0.3 million) recognized to reduce the tax benefit
available on share-based compensation costs recognized in the period.

As at June 30, 2020, the Company's Condensed Consolidated Balance Sheets include
net deferred income tax assets of $46.8 million, net of a valuation allowance of
$0.2 million (December 31, 2019 - $23.9 million). As at June 30, 2020, the
Company's Condensed Consolidated Balance Sheets include a deferred income tax
liability of $18.5 million (December 31, 2019 - $nil). During the six months
ended June 30, 2020, deferred tax assets increased by $22.9 million due to
losses recognized in the period. The recoverability of these deferred tax assets
is subject to certain levels of future taxable income and the uncertainties
associated with accounting estimates, as discussed in Note 1 of Notes to
Condensed Consolidated Financial Statements. Based on a review of the projected
future earnings of the Company there was no change in management's estimates of
the recoverability of the Company's deferred tax assets. Should actual results
differ from management's estimates of future taxable income, an increased
valuation allowance may be required.

The Company's Chinese subsidiary had taken a deduction for certain share-based
compensation issued by its parent company in a prior period and had recognized a
related deferred tax asset of $1.4 million (December 31, 2019 - $1.4 million).
Chinese regulatory authorities responsible for capital and exchange controls
will need to review and approve the proposed settlement of these transactions
before they can be completed. There may be a requirement for future investment
of funds into China in order to secure the deduction. Should the Company
proceed, any such future investment would come from existing capital invested in
the IMAX China group of companies being redeployed amongst the IMAX China group
of companies, including the Chinese subsidiary.

Equity Method Investments



For the six months ended June 30, 2020, the Company reported a loss of $0.5
million related its proportionate share of equity investee results, as compared
to $0.2 million in the same period in the prior year, due to the write-off of
deferred tax assets related to an equity method investment.

Non-Controlling Interests



The Company's Condensed Consolidated Financial Statements include the
non-controlling interest in the net income (loss) of IMAX China as well as the
impact of non-controlling interests in the activity of its Original Film Fund
subsidiary. For the six months ended June 30, 2020, the net loss attributable to
non-controlling interests of the Company's subsidiaries was $14.1 million (2019
- net income of $6.7 million).

                                       66

--------------------------------------------------------------------------------

LIQUIDITY AND CAPITAL RESOURCES

Credit Agreement



The Company has a credit agreement, the Fifth Amended and Restated Credit
Agreement, with Wells Fargo Bank, National Association ("Wells Fargo"), as
agent, and a syndicate of lenders party thereto (the "Credit Agreement"). The
Company's obligations under the Credit Agreement are guaranteed by certain of
its subsidiaries (the "Guarantors") and are secured by first-priority security
interests in substantially all the assets of the Company and the Guarantors. The
facility provided by the Credit Agreement (the "Credit Facility") matures on
June 28, 2023.

The Credit Agreement has a revolving borrowing capacity of $300.0 million, and
contains an uncommitted accordion feature allowing the Company to further expand
its borrowing capacity to $440.0 million or greater, subject to certain
conditions, depending on the mix of revolving and term loans comprising the
incremental facility.

In the first quarter of 2020, in response to uncertainties associated with the
outbreak of the COVID-19 global pandemic and its impact on the Company's
business, the Company drew down the $280.0 million in available borrowing
capacity under the Credit Facility, resulting in total outstanding borrowings of
$300.0 million.

The Credit Agreement contains a covenant that requires the Company to maintain a
Senior Secured Net Leverage Ratio (as defined in the Credit Agreement), as at
the last day of any Fiscal Quarter (as defined in the Credit Agreement) of no
greater than 3.25:1.00. In addition, the Credit Agreement contains customary
affirmative and negative covenants, including covenants that limit indebtedness,
liens, capital expenditures, asset sales, investments and restricted payments,
in each case subject to negotiated exceptions and baskets. The Credit Agreement
also contains customary representations, warranties and event of default
provisions.

On June 10, 2020, the Company entered into the First Amendment to the Credit
Agreement (the "Amendment"), which, among other things, (i) suspends the Senior
Secured Net Leverage Ratio covenant through the first quarter of 2021, (ii)
re-establishes the Senior Secured Net Leverage Ratio covenant thereafter,
provided that for subsequent quarters that such covenant is tested, as
applicable, the Company will be permitted to use its quarterly EBITDA (as
defined in the Credit Agreement) from the third and fourth quarters of 2019 in
lieu of the EBITDA for the corresponding quarters of 2020, (iii) adds a $75.0
million minimum liquidity covenant measured at the end of each calendar month
and (iv) restricts the Company's ability to make certain restricted payments,
dispositions and investments, create or assume liens and incur debt that would
otherwise have been permitted by the Credit Agreement. The modifications to the
negative covenants, the minimum liquidity covenant and modifications to certain
other provisions in the Credit Agreement pursuant to the Amendment were
effective from the date of the Amendment until the earlier of the delivery of
the compliance certificate for the fourth quarter of 2021 and the date on which
the Company, in its sole discretion, elects to calculate its compliance with the
Senior Secured Net Leverage Ratio by using either its actual EBITDA or
annualized EBITDA (the "Designated Period"). The Company was in compliance with
all of its requirements under the Credit Agreement, as amended, as at June 30,
2020, and based on current projections expects to be in compliance through at
least the next year.

Borrowings under the Credit Facility bear interest, at the Company's option, at
(i) LIBOR plus a margin ranging from 1.00% to 1.75% per annum; or (ii) the U.S.
base rate plus a margin ranging from 0.25% to 1.00% per annum, in each case
depending on the Company's Total Leverage Ratio (as defined in the Credit
Agreement); provided, however, that from the effective date of the Amendment
until the Company delivers a compliance certificate under the Credit Facility
following the end of the Designated Period, the applicable margin for LIBOR
borrowings will be 2.50% per annum and the applicable margin for U.S. base rate
borrowings will be 1.75% per annum. The effective interest rate for the three
and six months ended June 30, 2020 was 1.83% and 1.86%, respectively (2019 -
3.52% and 3.55%, respectively).

In addition, the Credit Facility has standby fees ranging from 0.25% to 0.38% per annum, based on the Company's Total Leverage Ratio with respect to the unused portion of the Credit Facility; provided, however, that from the effective date of the Amendment until the Company delivers a compliance certificate under the Credit Facility following the end of the Designated Period, the standby fee will be 0.50% per annum.



The Company incurred fees of approximately $1.0 million in connection with the
Amendment, which are being amortized on a straight-line basis through December
31, 2021.

See "Management's Discussion and Analysis of Financial Condition and Results of
Operations - Impact of COVID-19 Pandemic" in Item 2 of this Form 10-Q and "Risk
Factors - The Company has experienced a significant decrease in its revenues,
earnings and cash flows due to the COVID-19 global pandemic and its business,
financial condition and results of operations may continue to be significantly
harmed in future reporting periods" in Part II, Item 1A of this Form 10-Q.

                                       67

--------------------------------------------------------------------------------

Working Capital Facility



On July 24, 2019, IMAX (Shanghai) Multimedia Technology Co., Ltd. ("IMAX
Shanghai"), the Company's majority-owned subsidiary in China, renewed its
unsecured revolving facility for up to 200.0 million Renminbi (approximately
$30.0 million) to fund ongoing working capital requirements (the "Working
Capital Facility"). As at June 30, 2020, there was 1.7 million Renminbi ($0.2
million) in borrowings outstanding under the Working Capital Facility, and 198.3
million Renminbi ($29.8 million) was available for future borrowings. There were
no amounts drawn under the Working Capital facility at December 31, 2019. The
amounts available for borrowing under the Working Capital Facility are not
subject to a standby fee. The effective interest rate for the three and six
months ended June 30, 2020 was 4.35%, respectively. Subsequent to June 30, 2020,
IMAX Shanghai renewed its Working Capital Facility.

Letters of Credit and Other Commitments

As at June 30, 2020, the Company did not have any letters of credit or advance payment guarantees outstanding (December 31, 2019 - $nil), under the Credit Facility.



On October 28, 2019, the Company entered into a $5.0 million facility for
advance payment guarantees and letters of credit through the National Bank of
Canada for use solely in conjunction with guarantees fully insured by Export
Development Canada (the "NBC Facility") to replace a Bank of Montreal Facility
with substantially the same terms which expired on September 30, 2019. The NBC
Facility is unsecured and includes typical affirmative and negative covenants,
including delivery of annual consolidated financial statements within 120 days
of the end of the fiscal year. As at June 30, 2020, the Company did not have any
letters of credit or advance payment guarantees outstanding under the NBC
Facility.

Cash and Cash Equivalents



As of June 30, 2020, the Company's principal sources of liquidity included: (i)
its balances of cash and cash equivalents ($319.0 million, which reflects the
full draw of the Credit Facility in the first quarter of 2020), (ii) the
anticipated collection of trade accounts receivable, which includes amounts owed
under joint revenue sharing arrangements and DMR agreements with movie studios,
(iii) the anticipated collection from financing receivables due in the next
12 months and (iv) payments expected in the next 12 months on its existing sales
and sales type lease backlog.

The Company's $319.0 million balance of cash and cash equivalents as of June 30,
2020 includes $75.0 million in cash held outside of Canada (December 31, 2019 -
$90.1 million), of which $61.5 million was held in the People's Republic of
China (the "PRC") (December 31, 2019 - $67.6 million). In the first quarter of
2020, management completed a reassessment of its strategy with respect to the
most efficient means of deploying the Company's capital resources globally.
Based on the results of this reassessment, management concluded that the
historical earnings of certain foreign subsidiaries in excess of amounts
required to sustain business operations would no longer be indefinitely
reinvested. As a result, during the six months ended June 30, 2020, the Company
recognized a deferred tax liability of $18.5 million for the applicable foreign
withholding taxes associated with these historical earnings, which will become
payable upon the repatriation of any such earnings.

During the six months ended June 30, 2020, cash and cash equivalents increased
by $209.5 million, which reflects the full draw of the Credit Facility in the
first quarter of 2020, as discussed above. This financing cash inflow was
partially offset by $20.9 million in cash used to fund the Company's operating
activities as the COVID-19 global pandemic resulted in a significant decline in
revenue and earnings. In addition, during the six months ended June 30, 2020,
the Company repurchased $36.6 million of its common shares under the share
repurchase program and invested $3.9 million in equipment to be used in its
joint revenue sharing arrangements with exhibitors. Based on management's
current operating plan for 2020, the Company expects to continue to use cash to
deploy additional IMAX Theater Systems under joint revenue sharing arrangements.

The Company's operating cash flow will be adversely affected if management's
projections of future signings for IMAX Theater Systems and film performance,
theater installations and film productions are not realized. The Company
forecasts its short-term liquidity requirements on a quarterly and annual basis.
Since the Company's future cash flows are based on estimates and there may be
factors that are outside of the Company's control (see "Risk Factors" in Item 1A
in the Company's 2019 Form 10-K), there is no guarantee that the Company will
continue to be able to fund its operations through cash flows from operations.
Under the terms of the Company's typical sale and sales-type lease agreements,
the Company receives substantial cash payments before the Company completes the
performance of its obligations. Similarly, the Company receives cash payments
for some of its film productions in advance of related cash expenditures.


                                       68

--------------------------------------------------------------------------------


The repercussions of the COVID-19 global pandemic have resulted in a significant
decrease in the Company's revenues, earnings and operating cash flows during the
three and six months ended June 30, 2020 as GBO results declined significantly,
the installation of certain theater systems was delayed, and maintenance
services were generally suspended. During the time period when a significant
number of theaters in the IMAX network are closed, the Company has and will
continue to experience a significant decline in earnings and operating cash
flows as it is generating significantly lower than normal levels of GBO-based
revenue from its joint revenue sharing arrangements and digital remastering
services, it is unable to provide normal maintenance services to any of the
theaters that remain closed, and while some installation activity is continuing,
certain theater system installations have, and may continue to be delayed. In
addition, the Company has experienced and may continue to experience delays in
collecting payments due under existing theater sale or lease arrangements from
its exhibitor partners who are facing financial difficulties as a result of the
theater closures.

Based on the Company's current cash balances and operating cash flows, it expects to have sufficient capital and liquidity to fund its operations in the normal course for the next 12 months.



See "Management's Discussion and Analysis of Financial Condition and Results of
Operations - Impact of COVID-19 Pandemic" in Item 2 of this Form 10-Q and "Risk
Factors - The Company has experienced a significant decrease in its revenues,
earnings and cash flows due to the COVID-19 global pandemic and its business,
financial condition and results of operations may continue to be significantly
harmed in future reporting periods" in Part II, Item 1A of this Form 10-Q.

Operating Activities



The Company's net cash used in or provided by operating activities is affected
by a number of factors, including: (i) the level of cash collections from
customers in respect of existing IMAX Theater System sale and lease agreements,
(ii) the amount of upfront payments collected from newly signed IMAX Theater
System sale and lease agreements, (iii) the box-office performance of films
distributed by the Company and/or released to IMAX theaters, (iv) the level of
inventory purchases and (v) the level of the Company's operating expenses,
including expenses for research and development and new business initiatives.

Net cash used in operating activities totaled $20.9 million for the six months
ended June 30, 2020 as compared to net cash provided by operating activities of
$48.5 million for the six months ended June 30, 2019. In the six months ended
June 30, 2020, the net cash outflow from operating activities is principally due
to the significant decrease in the Company's revenue and earnings as a result of
the COVID-19 global pandemic. In addition, the Company has experienced a
slowdown in manufacturing, shipments and installation of IMAX Theater Systems at
customer sites, resulting in an increase in inventories. These cash outflows are
partially offset by a $37.0 million decrease in accounts receivable.

Investing Activities



Net cash used in investing activities totaled $5.7 million for the six months
ended June 30, 2020, which includes $3.9 million invested in equipment to be
used in the Company's joint revenue sharing arrangements with exhibitors. In
addition, the Company acquired $1.2 million of intangible asset, principally
related to the purchase or development of software, and purchased $0.6 million
of property, plant and equipment. In the six months ended June 30, 2019, net
cash used in investing activities totaled $42.7 million including the purchase
by IMAX China (Hong Kong), Limited, a wholly-owned subsidiary of IMAX China of
equity securities in Maoyan for $15.2 million.

Capital expenditures, including the Company's investment in joint revenue
sharing equipment, purchase of property, plant and equipment, other intangible
assets and investments in film assets were $9.8 million for the six months ended
June 30, 2020 as compared to $35.7 million for the six months ended June 30,
2019.

Financing Activities

Net cash provided by financing activities totaled $235.7 million for the six
months ended June 30, 2020, as compared to $41.3 million used in financing
activities in the six months ended June 30, 2019. During the six months ended
June 30, 2020, the net cash provided by financing activities was principally due
to the $280.0 million in Credit Facility borrowings drawn in the first quarter
of 2020, as discussed above, and $0.2 million drawn on IMAX China's Working
Capital Facility, partially offset by $36.6 million paid to repurchase common
shares under the Company's share repurchase program, $3.3 million paid to
purchase treasury stock for the settlement of restricted share units and related
taxes, $1.5 million for the repurchase of common shares under the IMAX China
share repurchase program, $2.1 million of dividends paid to the non-controlling
interest shareholders of IMAX China and $1.0 million in credit agreement
amendment fees.


                                       69

--------------------------------------------------------------------------------

CONTRACTUAL OBLIGATIONS



Payments to be made by the Company under contractual obligations as at June 30,
2020 are as follows:



                                                                   Payments Due by Period
                                         Total         Less Than
(In thousands of U.S. Dollars)         Obligation       One Year       1 to 3 years      3 to 5 years       Thereafter
Purchase obligations(1)               $     36,035     $   34,063     $        1,960     $           -     $         12
Pension obligations(2)                      20,298              -             20,298                 -                -
Operating lease obligations(3)              20,512          3,680              4,827             3,861            8,144
Credit Facility(4)                         300,000              -            300,000                 -                -
Working Capital Facility(5)                    244            244                  -                 -                -
Postretirement benefits obligations          2,151            103                217               236            1,595
                                      $    379,240     $   38,090     $      327,302     $       4,097     $      9,751

(1) Represents total payments to be made under binding commitments with suppliers

and outstanding payments to be made for supplies ordered, but yet to be

invoiced.

(2) The Company has an unfunded defined benefit pension plan, the SERP, covering

Mr. Gelfond, with a fixed benefit payable of $20.3 million. The table above

assumes that Mr. Gelfond will receive a lump sum payment of $20.3 million six

months after retirement at the end of the term of his current employment

agreement (December 31, 2022) in accordance with the terms of the SERP,

although Mr. Gelfond has not informed the Company that he intends to retire

at that time.

(3) Represents total minimum annual rental payments to be made under operating

leases, mostly consisting of rent at the Company's property in New York and

at the various owned and operated theaters.

(4) The Company is not required to make any minimum payments on the Credit

Facility.

(5) Subsequent to June 30, 2020, IMAX Shanghai renewed its Working Capital Facility.

Pension and Postretirement Obligations



The Company has an unfunded defined benefit pension plan, the SERP, covering Mr.
Gelfond. Pursuant to an amendment dated November 1, 2019 to an existing
employment agreement, the term of Mr. Gelfond's employment was extended through
December 31, 2022, although Mr. Gelfond has not informed the Company that he
intends to retire at that time. Under the terms of the amendment to his
employment agreement, the total amount of benefit payable to Mr. Gelfond under
the SERP has been fixed at $20.3 million. As at June 30, 2020, the Company's
Condensed Consolidated Balance Sheet includes the related benefit obligation of
approximately $19.0 million recorded within accrued and other liabilities
(December 31, 2019- $18.8 million).

The Company has a postretirement plan to provide health and welfare benefits to
Canadian employees meeting certain eligibility requirements. As at June 30,
2020, the Company's Condensed Consolidated Balance Sheet includes an unfunded
benefit obligation of $1.5 million recorded within accrued and other liabilities
(December 31, 2019 - $1.6 million).

In July 2000, the Company agreed to maintain health benefits for Messrs. Gelfond
and Bradley J. Wechsler, the Company's former Co-CEO and current Chairman of its
Board of Directors, upon retirement. As at June 30, 2020, the Company's
Condensed Consolidated Balance Sheet includes an unfunded benefit obligation of
$0.6 million recorded within accrued and other liabilities (December 31, 2019 -
$0.7 million).

The Company maintained a nonqualified deferred compensation benefit plan (the
"Retirement Plan") covering the former CEO of IMAX Entertainment and Senior
Executive Vice President of the Company. Under the terms of the Retirement Plan,
the benefits were due to vest in full if he incurred a separation from service
(as defined therein). In the fourth quarter of 2018, the executive incurred a
separation from service, and as such, the Retirement Plan benefits became fully
vested as at December 31, 2018 and the accelerated costs were recognized and
reflected in Executive Transition Costs in the Consolidated Statement of
Operations. As at June 30, 2020, the Company's Condensed Consolidated Balance
Sheet includes a funded benefit obligation of $3.6 million recorded within
accrued and other liabilities (December 31, 2019 -$3.6 million).



RECENTLY ISSUED ACCOUNTING STANDARDS



See Note 3 of Notes to Condensed Consolidated Financial Statements in Item 1 for
a discussion of recently issued accounting standards and their impact on the
Company's financial statements.

                                       70

--------------------------------------------------------------------------------

NON-GAAP FINANCIAL MEASURES



GAAP refers to generally accepted accounting principles in the United States of
America. In this report, the Company presents financial measures in accordance
with GAAP and also on a non-GAAP basis under U.S. Securities and Exchange
Commission rules. Specifically, the Company presents the following non-GAAP
financial measures as supplemental measures of its performance:



  • Adjusted net (loss) income attributable to common shareholders;



• Adjusted net (loss) income attributable to common shareholders per basic and


     diluted share;




  • EBITDA; and




  • Adjusted EBITDA per Credit Facility.


Adjusted net (loss) income attributable to common shareholders and adjusted net
(loss) income attributable to common shareholders per basic and diluted share
exclude, where applicable: (i) share-based compensation; (ii) exit costs,
restructuring charges and associated impairments, (iii) changes in the fair
value of equity investments, (iv) COVID-19 government relief benefits, as well
as the related tax impact of these adjustments, and (v) the income tax effects
related to the removal of the indefinitely reinvested assertion on the
historical earnings of certain subsidiaries.

The Company believes that these non-GAAP financial measures are important
supplemental measures that allow management and users of the Company's financial
statements to view operating trends and analyze controllable operating
performance on a comparable basis between periods without the after-tax impact
of share-based compensation and certain unusual items included in net (loss)
income attributable to common shareholders. Although share-based compensation is
an important aspect of the Company's employee and executive compensation
packages, it is a non-cash expense and is excluded from certain internal
business performance measures.

A reconciliation of net (loss) income attributable to common shareholders and
the comparable per share amounts, the most directly comparable GAAP measures, to
adjusted net (loss) income attributable to common shareholders and adjusted net
(loss) income attributable to common shareholders per diluted share is presented
in the table below. The Company believes that net (loss) income attributable to
common shareholders is the most directly comparable GAAP measure because it
reflects the earnings relevant to the Company's shareholders, rather than
including the non-controlling interest. As such, beginning in the first quarter
of 2020, the Company has updated the reconciliations for such non-GAAP financial
measures included herein.



                                              Three Months Ended                    Three Months Ended
                                                 June 30, 2020                        June 30, 2019
(In thousands of U.S. dollars, except
per share amounts)                       Net Loss         Diluted EPS         Net Income         Diluted EPS
Reported net (loss) income
attributable to common shareholders      $ (25,967 )     $       (0.44 )     $     11,397       $        0.19
Adjustments(1):
Share-based compensation                     6,168                0.10       $      6,799                0.11
Changes in the fair value of equity
securities                                  (1,413 )             (0.02 )            3,101                0.05
COVID-19 government relief benefits         (3,151 )             (0.05 )                -                   -
Tax impact on items listed above              (857 )             (0.01 )           (1,604 )             (0.03 )
Income tax effects related to the
removal of the indefinitely reinvested
assertion on the historical earnings
of certain subsidiaries                       (841 )             (0.02 )                -                   -
Adjusted net (loss) income(1)            $ (26,061 )     $       (0.44 )

$ 19,693 $ 0.32



Weighted average basic shares
outstanding                                                     58,808                                 61,331
Weighted average diluted shares
outstanding                                                     58,808                                 61,507




                                       71

--------------------------------------------------------------------------------



                                               Six Months Ended                   Six Months Ended
                                                  June 30, 2020                    June 30, 2019
(In thousands of U.S. dollars, except
per share amounts)                         Net Loss       Diluted EPS       Net Income       Diluted EPS
Reported net (loss) income attributable
to common shareholders                     $ (75,321 )   $       (1.26 )   $     19,662     $        0.32
Adjustments(1):
Share-based compensation                      10,243              0.17           11,076              0.18
Exit costs, restructuring charges and
associated impairments                             -                 -              850              0.01
Change in the fair value of equity
securities                                     1,752              0.03            1,401              0.03
COVID-19 government relief benefits           (3,151 )           (0.05 )              -                 -
Tax impact on items listed above              (1,195 )           (0.02 )         (2,484 )           (0.04 )
Income tax effects related to the
removal of the indefinitely reinvested
assertion on the historical earnings of
certain subsidiaries                          12,885              0.21                -                 -
Adjusted net (loss) income(1)              $ (54,787 )   $       (0.92 )

$ 30,505 $ 0.50



Weighted average basic shares
outstanding                                                     59,613                             61,354
Weighted average diluted shares
outstanding                                                     59,613                             61,525



(1) Reflects amounts attributable to common shareholders.




In addition to the non-GAAP financial measures discussed above, management also
uses "EBITDA," as such term is defined in the Credit Agreement, and which is
referred to herein as "Adjusted EBITDA per Credit Facility." As allowed by the
Credit Agreement, Adjusted EBITDA per Credit Facility includes adjustments in
addition to the exclusion of interest, taxes, depreciation and amortization.
Accordingly, this non-GAAP financial measure is presented to allow a more
comprehensive analysis of the Company's operating performance and to provide
additional information with respect to the Company's compliance against its
Credit Agreement requirements in the current period, if applicable. In addition,
the Company believes that Adjusted EBITDA per Credit Facility presents relevant
and useful information widely used by analysts, investors and other interested
parties in the Company's industry to evaluate, assess and benchmark the
Company's results.

EBITDA is defined as net (loss) income excluding: (i) interest expense, net of
interest income; (ii) income tax (benefit) expense; and (iii) depreciation and
amortization, including film asset amortization. Adjusted EBITDA per Credit
Facility is defined as EBITDA excluding: (i) share-based and other non-cash
compensation; (ii) gain (loss) in fair value of equity investment; (iii)
write-downs, net of recoveries, including asset impairments and credit loss
expense; and (iv) (gain) loss from equity accounted investments.

A reconciliation of net loss attributable to common shareholders, the most
directly comparable GAAP measure, to EBITDA and Adjusted EBITDA per Credit
Facility is presented in the table below. The Company believes that net loss
attributable to common shareholders is the most directly comparable GAAP measure
because it reflects the earnings relevant to the Company's shareholders, rather
than including the non-controlling interest. As such, beginning in the first
quarter of 2020, the Company has updated the reconciliations for such non-GAAP
financial measures included herein.

                                       72

--------------------------------------------------------------------------------


                                                         For the Three 

Months Ended June 30, 2020 (1)


                                           Attributable to
                                           Non-controlling
                                            Interests and            Less: Attributable to          Attributable to
                                                                        Non-controlling
                                         Common Shareholders               Interests              Common Shareholders
(In thousands of U.S. Dollars)
Reported net loss                       $              (30,047 )     $              (4,080 )    $               (25,967 )
Add (subtract):
Income tax (benefit) expense                           (10,248 )                       638                      (10,886 )
Interest expense, net of interest
income                                                     524                         (96 )                        620
Depreciation and amortization,
including film asset amortization                       11,930                       1,049                       10,881
EBITDA                                  $              (27,841 )     $              (2,489 )    $               (25,352 )
Share-based and other non-cash
compensation                                             6,541                         299                        6,242
Gain in fair value of equity investment                 (2,025 )                      (612 )                     (1,413 )
Write-downs, including asset
impairments and credit loss expense                      3,843                       1,815                        2,028
Adjusted EBITDA per Credit Facility     $              (19,482 )     $                (987 )    $               (18,495 )






                                                         For the Twelve

Months Ended June 30, 2020 (1)


                                           Attributable to
                                           Non-controlling
                                            Interests and            Less: Attributable to           Attributable to
                                                                        Non-controlling
                                         Common Shareholders               Interests               Common Shareholders
(In thousands of U.S. Dollars)
Reported net loss                       $              (57,210 )     $              (9,093 )     $               (48,117 )
Add (subtract):
Income tax expense                                      13,069                       6,707                         6,362
Interest expense, net of interest
income                                                     922                        (424 )                       1,346
Depreciation and amortization,
including film asset amortization                       60,865                       4,897                        55,968
EBITDA                                  $               17,646       $               2,087       $                15,559
Share-based and other non-cash
compensation                                            22,710                         730                        21,980
Loss in fair value of equity investment                    978                         274                           704
Write-downs, including asset
impairments and credit loss expense                     23,404                       5,420                        17,984
Loss from equity accounted investments                     304                           -                           304
Adjusted EBITDA per Credit Facility     $               65,042       $               8,511       $                56,531



(1) Senior Secured Net Leverage Ratio calculated using twelve months ended

Adjusted EBITDA per Credit Facility. During the second quarter of 2020, the

Company entered into the Amendment to the Credit Facility Agreement which

provides for, among other things, the suspension of the Senior Secured Net

Leverage Ratio financial covenant through the first quarter of 2021. For more

information see Note 7 of Notes to Condensed Consolidated Financial

Statements.




The Company cautions users of its financial statements that these non-GAAP
financial measures may not be comparable to similarly titled measures reported
by other companies. Additionally, the non-GAAP financial measures used by the
Company should not be considered as a substitute for, or superior to, the
comparable GAAP amounts.

OFF-BALANCE SHEET ARRANGEMENTS

There are currently no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on the Company's financial condition.



                                       73

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses